Evidence map›Paper›PMID 34959507›Full record

ArticlePathogens (Basel, Switzerland)2021

Synergistic Combination of AS101 and Azidothymidine against Clinical Isolates of Carbapenem-Resistant

Chung-Lin Sung, Wei-Chun Hung, Po-Liang Lu, Lin Lin, Liang-Chun Wang, Tsung-Ying Yang, Sung-Pin Tseng

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chung-Lin SungDepartment of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Wei-Chun HungDepartment of Microbiology and Immunology, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Po-Liang LuCenter for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan.ORCID 0000-0002-7423-6783
Lin LinDepartment of Culinary Art, I-Shou University, Kaohsiung 84001, Taiwan.
Liang-Chun WangDepartment of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan.ORCID 0000-0002-4977-4256
Tsung-Ying YangDepartment of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan.ORCID 0000-0001-8579-0299
Sung-Pin TsengDepartment of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan.

Funding

Kaohsiung Medical University Drug Development and Value Creation Research Center KMU-TC109A03-6Ministry of Science and Technology of Taiwan MOST 109-2320-B-037-027National Sun Yat-sen University-Kaohsiung Medical University (NSYSU-KMU) Joint Research Project NSYSUKMU 109-I005National Sun Yat-sen University-Kaohsiung Medical University (NSYSU-KMU) Joint Research Project NSYSUKMU 110-I004
6 · The paper itself

Abstract

Owing to the over usage of carbapenems, carbapenem resistance has become a vital threat worldwide, and, thus, the World Health Organization announced the carbapenem-resistant Enterobacteriaceae (CRE) as the critical priority for antibiotic development in 2017. In the current situation, combination therapy would be one solution against CRE. Azidothymidine (AZT), a thymidine analog, has demonstrated its synergistically antibacterial activities with other antibiotics. The unexpected antimicrobial activity of the immunomodulator ammonium trichloro(dioxoethylene-

Indexed as

AS101azidothymidinecarbapenem-resistant Enterobacteriaceae (CRE)synergistic activity

Identifiers

PMID34959507
PMCPMC8706163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.